Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mip-1095 I-123 SCHEMBL17558049 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| Mip-1095 I-123 SCHEMBL4326617 | 1.00 | FOLH1 (1.00) | FOLH1 | |
| SCHEMBL24354421 | 0.95 | FOLH1 (0.91) | FOLH1 | |
| SCHEMBL16654681 | 0.95 | FOLH1 (0.91) | FOLH1 | |
| SCHEMBL4326624 | 0.95 | FOLH1 (0.91) | FOLH1 | |
| SCHEMBL11977615 | 0.92 | FOLH1 (0.84) | FOLH1 | |
| SCHEMBL11977608 | 0.92 | FOLH1 (0.84) | FOLH1 | |
| SCHEMBL13287695 | 0.91 | FOLH1 (0.83) | FOLH1 | |
| SCHEMBL23077794 | 0.91 | FOLH1 (0.82) | FOLH1 | |
| SCHEMBL11977601 | 0.89 | FOLH1 (1.00) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099626-A1 | METHODS AND SYSTEMS FOR MANUFACTURING RADIOPHARMACEUTICALS | NOVARTIS AG (CH) | 2026-05-15 | — | — | WO | claimed |
| WO-2026088112-A1 | COMBINATION THERAPIES WITH AR-DEGRADING AGENTS AND PSMA-TARGETING RADIOLIGANDS | NOVARTIS AG (CH) | 2026-04-30 | — | — | WO | claimed |
| EP-4554621-A1 | COMBINED THERAPY WITH NANOPARTICLES AND RADIOPHARMACEUTICALS | UNIVERSITE DE MONTPELLIER (FR) | 2025-05-21 | — | — | EP | claimed |
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY | 2025-02-27 | — | — | US | claimed |
| WO-2025038942-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN AS AN IMAGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-02-20 | — | — | WO | claimed |
| CN-110730908-B | Engineered cells expressing Prostate Specific Membrane Antigen (PSMA) or modified versions thereof and related methods | 朱诺治疗学股份有限公司 | 2025-01-21 | — | — | CN | claimed |
| WO-2024013272-A1 | COMBINED THERAPY WITH NANOPARTICLES AND RADIOPHARMACEUTICALS | UNIVERSITE DE MONTPELLIER (FR) | 2024-01-18 | — | — | WO | claimed |
| US-20230364271-A1 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | CORNELL UNIVERSITY | 2023-11-16 | — | — | US | claimed |
| WO-2023154939-A2 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-17 | — | — | WO | claimed |
| EP-4221763-A1 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | Cornell University (US) | 2023-08-09 | — | — | EP | claimed |
| US-20230190796-A1 | ENGINEERED CELLS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) OR A MODIFIED FORM THEREOF AND RELATED METHODS | JUNO THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| WO-2022072292-A1 | METHODS AND COMPOSITIONS FOR INCREASING UPTAKE, INTERNALIZATION, AND/OR RETENTION OF SMALL MOLECULE LIGANDS | CORNELL UNIVERSITY (US) | 2022-04-07 | — | — | WO | claimed |
| EP-4746926-A2 | PSMA-TARGETING RADIOLIGAND TREATMENT REGIMEN | Novartis AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743125-A1 | METHOD OF TREATING PROSTATE CANCER | Novartis AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026099626-A1 | METHODS AND SYSTEMS FOR MANUFACTURING RADIOPHARMACEUTICALS | NOVARTIS AG (CH) | 2026-05-15 | — | — | WO | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008058192-A2 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | FOLH1 4/4885 |
| US-20080193381-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885 |
| US-20250064948-A1 | GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING | DGKI, PGC, MPC2 | FOLH1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.